[
  {
    "ts": null,
    "headline": "Novo Nordisk A/S: Candidate for the Board of Directors will not seek election",
    "summary": "Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting. Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk Board of Dire",
    "url": "https://finnhub.io/api/news?id=b77da557ca900f94bc96516c1a1caa7c9553a81727001ae6f4852479935f65b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763073480,
      "headline": "Novo Nordisk A/S: Candidate for the Board of Directors will not seek election",
      "id": 137477019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting. Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk Board of Dire",
      "url": "https://finnhub.io/api/news?id=b77da557ca900f94bc96516c1a1caa7c9553a81727001ae6f4852479935f65b8"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
    "summary": "Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index and the Health",
    "url": "https://finnhub.io/api/news?id=5d95015b84f1a6cebbeec59a2b7f96fafa404e92f671da44cd3c09ba3f807718",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763066682,
      "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
      "id": 137477020,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index and the Health",
      "url": "https://finnhub.io/api/news?id=5d95015b84f1a6cebbeec59a2b7f96fafa404e92f671da44cd3c09ba3f807718"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO says RFK Jr. wasn't his 'first choice' for HHS Secretary",
    "summary": "Pfizer CEO says RFK Jr.'s appointment was not up to him, though he has found common ground with the vaccine skeptic.",
    "url": "https://finnhub.io/api/news?id=d4126e4b8c946612fb9898e05c34b5229136d01259e00e6f137c36c61f118baa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763064762,
      "headline": "Pfizer CEO says RFK Jr. wasn't his 'first choice' for HHS Secretary",
      "id": 137473237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer CEO says RFK Jr.'s appointment was not up to him, though he has found common ground with the vaccine skeptic.",
      "url": "https://finnhub.io/api/news?id=d4126e4b8c946612fb9898e05c34b5229136d01259e00e6f137c36c61f118baa"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer completes Metsera acquisition in deal worth up to $10 bn",
    "summary": "US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.",
    "url": "https://finnhub.io/api/news?id=ae26ef084288cbe588c33e98581f63f22d32d3163fc91ed3cdefdf9024a9d550",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763062711,
      "headline": "Pfizer completes Metsera acquisition in deal worth up to $10 bn",
      "id": 137473238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.",
      "url": "https://finnhub.io/api/news?id=ae26ef084288cbe588c33e98581f63f22d32d3163fc91ed3cdefdf9024a9d550"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. would not have been my HHS pick: Pfizer CEO",
    "summary": "Health and Human Services Secretary Robert F. Kennedy, Jr. has come under fire for his views on vaccines. In an interview with Yahoo Finance, Pfizer (PFE) CEO Albert Bourla says that Kennedy wouldn't have been his pick to lead HHS. Find out why in the video above. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
    "url": "https://finnhub.io/api/news?id=1ebf555e526e61442f223c1674cd141b83519b9d645271b571e74c8e73bffd15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763062200,
      "headline": "RFK Jr. would not have been my HHS pick: Pfizer CEO",
      "id": 137473239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health and Human Services Secretary Robert F. Kennedy, Jr. has come under fire for his views on vaccines. In an interview with Yahoo Finance, Pfizer (PFE) CEO Albert Bourla says that Kennedy wouldn't have been his pick to lead HHS. Find out why in the video above. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
      "url": "https://finnhub.io/api/news?id=1ebf555e526e61442f223c1674cd141b83519b9d645271b571e74c8e73bffd15"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are Blowing Past the S&P 500. What Could Be Behind the Rally.",
    "summary": "The sector is up almost 7% since the start of November, while the broader market is down more than 1%.",
    "url": "https://finnhub.io/api/news?id=057b3ef5d4f251548d7ff892ad25c74df59ae9e7db709f2f5862821d1da51f14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763061600,
      "headline": "Healthcare Stocks Are Blowing Past the S&P 500. What Could Be Behind the Rally.",
      "id": 137473199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The sector is up almost 7% since the start of November, while the broader market is down more than 1%.",
      "url": "https://finnhub.io/api/news?id=057b3ef5d4f251548d7ff892ad25c74df59ae9e7db709f2f5862821d1da51f14"
    }
  },
  {
    "ts": null,
    "headline": "Activist investor Jeff Smith: How Starboard 'lights a fire' under Corporate America",
    "summary": "Starboard’s Jeff Smith says activism isn’t about destruction — it’s about discipline, efficiency, and motivating complacent CEOs",
    "url": "https://finnhub.io/api/news?id=9797168a2dcd25e5c61cfac924a00628c3142485a9c8d71c0f7f051380079b4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763060333,
      "headline": "Activist investor Jeff Smith: How Starboard 'lights a fire' under Corporate America",
      "id": 137470622,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Starboard’s Jeff Smith says activism isn’t about destruction — it’s about discipline, efficiency, and motivating complacent CEOs",
      "url": "https://finnhub.io/api/news?id=9797168a2dcd25e5c61cfac924a00628c3142485a9c8d71c0f7f051380079b4a"
    }
  },
  {
    "ts": null,
    "headline": "BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?",
    "summary": "Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.",
    "url": "https://finnhub.io/api/news?id=29bda3e91c05f1eff9543fd18991f8fc0bea52076ad8d57b4e18e77cb1c103fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763059500,
      "headline": "BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?",
      "id": 137473211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.",
      "url": "https://finnhub.io/api/news?id=29bda3e91c05f1eff9543fd18991f8fc0bea52076ad8d57b4e18e77cb1c103fb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Dumps BioNTech Stake as Obesity Gold Rush Heats Up",
    "summary": "$508M share sale marks end of a Covid-era alliance--just as Pfizer doubles down on weight-loss moonshots",
    "url": "https://finnhub.io/api/news?id=19cad4eb68202d125528f7e31f69d428fad4383652441115971103166edcab94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763058282,
      "headline": "Pfizer Dumps BioNTech Stake as Obesity Gold Rush Heats Up",
      "id": 137470623,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "$508M share sale marks end of a Covid-era alliance--just as Pfizer doubles down on weight-loss moonshots",
      "url": "https://finnhub.io/api/news?id=19cad4eb68202d125528f7e31f69d428fad4383652441115971103166edcab94"
    }
  },
  {
    "ts": null,
    "headline": "Future of medicine will be profoundly impacted by AI: Pfizer CEO",
    "summary": "Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss the future of medicine and pharmaceuticals, and what impact he believes artificial intelligence (AI) will have.  For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
    "url": "https://finnhub.io/api/news?id=6b0cc23ae8cb8a1b0b362a2f208c7126e14736e3d81fbe0c07c6a79d62dc6a61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763057732,
      "headline": "Future of medicine will be profoundly impacted by AI: Pfizer CEO",
      "id": 137470624,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss the future of medicine and pharmaceuticals, and what impact he believes artificial intelligence (AI) will have.  For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
      "url": "https://finnhub.io/api/news?id=6b0cc23ae8cb8a1b0b362a2f208c7126e14736e3d81fbe0c07c6a79d62dc6a61"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Disney Shares Fall After Revenue Miss; Verizon to Cut Workforce by About 15,000 Jobs",
    "summary": "All three major US stock indexes were down after midday trading Thursday, following President Donald",
    "url": "https://finnhub.io/api/news?id=69162407038dfd98726ddbe2415f4bc71c73e003fd8a5868e7a78a0586a3b5a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763056823,
      "headline": "Top Midday Stories: Disney Shares Fall After Revenue Miss; Verizon to Cut Workforce by About 15,000 Jobs",
      "id": 137470581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were down after midday trading Thursday, following President Donald",
      "url": "https://finnhub.io/api/news?id=69162407038dfd98726ddbe2415f4bc71c73e003fd8a5868e7a78a0586a3b5a9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market",
    "summary": "Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a \"right to win\" on the obesity drugs that have become a major market.",
    "url": "https://finnhub.io/api/news?id=3f49f30335bfffdeb3ba47e6c365e5d5c93d007fb665c9c040a64b552344b322",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763054096,
      "headline": "Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market",
      "id": 137470176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a \"right to win\" on the obesity drugs that have become a major market.",
      "url": "https://finnhub.io/api/news?id=3f49f30335bfffdeb3ba47e6c365e5d5c93d007fb665c9c040a64b552344b322"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO: AI will help with medicine's next big breakthrough",
    "summary": "Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright. The company plans to enter the GLP-1 space by 2028 and aims to become a leader in the obesity market. Bourla also notes that the next big breakthrough in medicine could be aided by the use of artificial intelligence and discusses Pfizer's relationship with the White House. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
    "url": "https://finnhub.io/api/news?id=7b1054c12741cd5d1e534e3b7b5af1bd794c1823cc340f94c248f22766285f7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763053471,
      "headline": "Pfizer CEO: AI will help with medicine's next big breakthrough",
      "id": 137470177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright. The company plans to enter the GLP-1 space by 2028 and aims to become a leader in the obesity market. Bourla also notes that the next big breakthrough in medicine could be aided by the use of artificial intelligence and discusses Pfizer's relationship with the White House. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
      "url": "https://finnhub.io/api/news?id=7b1054c12741cd5d1e534e3b7b5af1bd794c1823cc340f94c248f22766285f7e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer plans to enter GLP-1 space by 2028, CEO explains",
    "summary": "Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to share that Pfizer will enter the obesity market by 2028 after paying $10B to acquire Metsera (MTSR). The drugmaker won out over rival Novo Nordisk (NVO) in its bid for the company. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
    "url": "https://finnhub.io/api/news?id=3598f5c4638e132ff797bd6468c6082c90162fd117344c1f55e49c76f117f4da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763053094,
      "headline": "Pfizer plans to enter GLP-1 space by 2028, CEO explains",
      "id": 137470178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to share that Pfizer will enter the obesity market by 2028 after paying $10B to acquire Metsera (MTSR). The drugmaker won out over rival Novo Nordisk (NVO) in its bid for the company. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
      "url": "https://finnhub.io/api/news?id=3598f5c4638e132ff797bd6468c6082c90162fd117344c1f55e49c76f117f4da"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Completes Acquisition of Metsera",
    "summary": "NEW YORK, November 13, 2025--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.",
    "url": "https://finnhub.io/api/news?id=bc4b3ef9ae3fa4ccd1f7e9d1094c173a5dca1e3bbdfa1cff8e9a6354781980cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763051160,
      "headline": "Pfizer Completes Acquisition of Metsera",
      "id": 137469231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, November 13, 2025--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.",
      "url": "https://finnhub.io/api/news?id=bc4b3ef9ae3fa4ccd1f7e9d1094c173a5dca1e3bbdfa1cff8e9a6354781980cc"
    }
  },
  {
    "ts": null,
    "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=5aafec13e5283a7c16cdd2ef7a281b860ab6773670749212b5df63a2284578b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763045138,
      "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
      "id": 137468541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=5aafec13e5283a7c16cdd2ef7a281b860ab6773670749212b5df63a2284578b0"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves midday: Walt Disney, Sweetgreen, Cisco, Planet Fitness and more",
    "summary": "These are the stocks posting the largest moves in midday trading.",
    "url": "https://finnhub.io/api/news?id=4ffd416b81e80274bcf2f11133a2f38a5dfdacfe6cf4b4ce6a5f98578f44931b",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763036305,
      "headline": "Stocks making the biggest moves midday: Walt Disney, Sweetgreen, Cisco, Planet Fitness and more",
      "id": 137469735,
      "image": "https://image.cnbcfm.com/api/v1/image/108173479-17527723282025-07-17t165324z_1832560291_rc2dofauzv30_rtrmadp_0_usa-stocks.jpeg?v=1754423887&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "These are the stocks posting the largest moves in midday trading. ",
      "url": "https://finnhub.io/api/news?id=4ffd416b81e80274bcf2f11133a2f38a5dfdacfe6cf4b4ce6a5f98578f44931b"
    }
  },
  {
    "ts": null,
    "headline": "Inside Yahoo Finance Invest 2025: Elon Musk's $1 trillion pay package, crypto cracks, and AI bubbles",
    "summary": "If you love investing or want to love investing, Yahoo Finance's annual Invest event is here to help!",
    "url": "https://finnhub.io/api/news?id=6e6e366ff24c14546c3b39a88cad2326b67197634b3af7b59bb83476b573a848",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763035269,
      "headline": "Inside Yahoo Finance Invest 2025: Elon Musk's $1 trillion pay package, crypto cracks, and AI bubbles",
      "id": 137467488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you love investing or want to love investing, Yahoo Finance's annual Invest event is here to help!",
      "url": "https://finnhub.io/api/news?id=6e6e366ff24c14546c3b39a88cad2326b67197634b3af7b59bb83476b573a848"
    }
  },
  {
    "ts": null,
    "headline": "Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results",
    "summary": "Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.",
    "url": "https://finnhub.io/api/news?id=ffadeaf36e17ebb713145df35d17b2ffb7aaa49ca9d2c42ab2ce744f4d01db40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763034600,
      "headline": "Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results",
      "id": 137468373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.",
      "url": "https://finnhub.io/api/news?id=ffadeaf36e17ebb713145df35d17b2ffb7aaa49ca9d2c42ab2ce744f4d01db40"
    }
  },
  {
    "ts": null,
    "headline": "CPHI 2025: ‘handprint’ metric bridges pharma sustainability and economic value",
    "summary": "The WifOR Institute’s ‘handprint’ quantifies positive socioeconomic impact of pharma products, positing a sustainability metric.",
    "url": "https://finnhub.io/api/news?id=7d8b0a6dd53cbb900c08bd52883b5f60ad8ed11a4a3bb487e0152e734eaca3ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763032987,
      "headline": "CPHI 2025: ‘handprint’ metric bridges pharma sustainability and economic value",
      "id": 137467041,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The WifOR Institute’s ‘handprint’ quantifies positive socioeconomic impact of pharma products, positing a sustainability metric.",
      "url": "https://finnhub.io/api/news?id=7d8b0a6dd53cbb900c08bd52883b5f60ad8ed11a4a3bb487e0152e734eaca3ee"
    }
  },
  {
    "ts": null,
    "headline": "Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?",
    "summary": "Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.",
    "url": "https://finnhub.io/api/news?id=56d63bb313d83eab53c6ea4d365b364b36030660921a8790422a648f1bfd874f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763027700,
      "headline": "Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?",
      "id": 137466939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.",
      "url": "https://finnhub.io/api/news?id=56d63bb313d83eab53c6ea4d365b364b36030660921a8790422a648f1bfd874f"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks Topping a 2025 List of Dividend Yields",
    "summary": "Turn health into wealth with these three high-yielding dividend stocks.",
    "url": "https://finnhub.io/api/news?id=89be9136e46271c1f51fa719d9a1970ed88a7ab94b062f94212b3f46955971d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762997220,
      "headline": "3 Healthcare Stocks Topping a 2025 List of Dividend Yields",
      "id": 137467043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Turn health into wealth with these three high-yielding dividend stocks.",
      "url": "https://finnhub.io/api/news?id=89be9136e46271c1f51fa719d9a1970ed88a7ab94b062f94212b3f46955971d9"
    }
  }
]